Division of Pfizer Inc.
Latest From Upjohn Laboratories
After only two multinationals managed to win bids in China's massive new centralized drug procurement scheme, other foreign firms were hoping to get a break in the second round. But this may not materialize.
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Leading Indian biologics firm Biocon reported first-quarter net profit soared more than 70% and said it is confident of a “very successful” US biosimilar trastuzumab launch, despite rival Amgen stealing a march by commercializing its own version first in the world’s largest drug market.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.